289 related articles for article (PubMed ID: 25890798)
1. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
Durheim MT; Collard HR; Roberts RS; Brown KK; Flaherty KR; King TE; Palmer SM; Raghu G; Snyder LD; Anstrom KJ; Martinez FJ;
Lancet Respir Med; 2015 May; 3(5):388-96. PubMed ID: 25890798
[TBL] [Abstract][Full Text] [Related]
2. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
4. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
5. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
Zappala CJ; Latsi PI; Nicholson AG; Colby TV; Cramer D; Renzoni EA; Hansell DM; du Bois RM; Wells AU
Eur Respir J; 2010 Apr; 35(4):830-6. PubMed ID: 19840957
[TBL] [Abstract][Full Text] [Related]
6. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
King TE; Albera C; Bradford WZ; Costabel U; Hormel P; Lancaster L; Noble PW; Sahn SA; Szwarcberg J; Thomeer M; Valeyre D; du Bois RM;
Lancet; 2009 Jul; 374(9685):222-8. PubMed ID: 19570573
[TBL] [Abstract][Full Text] [Related]
7. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.
Richeldi L; Ryerson CJ; Lee JS; Wolters PJ; Koth LL; Ley B; Elicker BM; Jones KD; King TE; Ryu JH; Collard HR
Thorax; 2012 May; 67(5):407-11. PubMed ID: 22426899
[TBL] [Abstract][Full Text] [Related]
8. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.
du Bois RM; Weycker D; Albera C; Bradford WZ; Costabel U; Kartashov A; Lancaster L; Noble PW; Raghu G; Sahn SA; Szwarcberg J; Thomeer M; Valeyre D; King TE
Am J Respir Crit Care Med; 2011 Aug; 184(4):459-66. PubMed ID: 21616999
[TBL] [Abstract][Full Text] [Related]
9. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Kreuter M; Wuyts W; Renzoni E; Koschel D; Maher TM; Kolb M; Weycker D; Spagnolo P; Kirchgaessler KU; Herth FJ; Costabel U
Lancet Respir Med; 2016 May; 4(5):381-9. PubMed ID: 27050871
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.
Salisbury ML; Xia M; Zhou Y; Murray S; Tayob N; Brown KK; Wells AU; Schmidt SL; Martinez FJ; Flaherty KR
Chest; 2016 Feb; 149(2):491-498. PubMed ID: 26425858
[TBL] [Abstract][Full Text] [Related]
11. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.
Assayag D; Vittinghoff E; Ryerson CJ; Cocconcelli E; Tonelli R; Hu X; Elicker BM; Golden JA; Jones KD; King TE; Koth LL; Lee JS; Ley B; Shum AK; Wolters PJ; Ryu JH; Collard HR
Respir Med; 2015 Aug; 109(8):1058-62. PubMed ID: 26140806
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
[TBL] [Abstract][Full Text] [Related]
13. Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.
Maher TM; Stowasser S; Voss F; Bendstrup E; Kreuter M; Martinez FJ; Sime PJ; Stock C
Respirology; 2023 Dec; 28(12):1147-1153. PubMed ID: 37646126
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.
Ley B; Bradford WZ; Vittinghoff E; Weycker D; du Bois RM; Collard HR
Am J Respir Crit Care Med; 2016 Sep; 194(6):711-8. PubMed ID: 26938706
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.
Wells JM; Farris RF; Gosdin TA; Dransfield MT; Wood ME; Bell SC; Rowe SM
Lancet Respir Med; 2016 Aug; 4(8):636-645. PubMed ID: 27298019
[TBL] [Abstract][Full Text] [Related]
16. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study.
Herazo-Maya JD; Sun J; Molyneaux PL; Li Q; Villalba JA; Tzouvelekis A; Lynn H; Juan-Guardela BM; Risquez C; Osorio JC; Yan X; Michel G; Aurelien N; Lindell KO; Klesen MJ; Moffatt MF; Cookson WO; Zhang Y; Garcia JGN; Noth I; Prasse A; Bar-Joseph Z; Gibson KF; Zhao H; Herzog EL; Rosas IO; Maher TM; Kaminski N
Lancet Respir Med; 2017 Nov; 5(11):857-868. PubMed ID: 28942086
[TBL] [Abstract][Full Text] [Related]
17. [Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis].
Behr J; Bonella F; Bonnet R; Gläser S; Grohé C; Günther A; Koschel D; Kreuter M; Kirsten D; Krögel C; Markart P; Müller-Quernheim J; Neurohr C; Pfeifer M; Prasse A; Schönfeld N; Schreiber J; Wirtz H; Witt C; Costabel U
Pneumologie; 2015 Aug; 69(8):455-8. PubMed ID: 26227628
[TBL] [Abstract][Full Text] [Related]
18. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
[TBL] [Abstract][Full Text] [Related]
19. Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi-centre registry cohort.
Marcoux V; Lok SD; Mondal P; Assayag D; Fisher JH; Shapera S; Morisset J; Manganas H; Fell CD; Hambly N; Cox PG; Kolb M; Gershon AS; To T; Sadatsafavi M; Khalil N; Wong AW; Wilcox PG; Ryerson CJ; Vu T; Johannson KA
Respirology; 2024 Jul; 29(7):596-604. PubMed ID: 38436522
[TBL] [Abstract][Full Text] [Related]
20. Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.
Toi Y; Takei R; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Fukuoka J; Johkoh T; Kondoh Y
Respir Investig; 2021 May; 59(3):335-341. PubMed ID: 33551330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
